Skip Navigation


JAC Advance Access originally published online on March 20, 2006
Journal of Antimicrobial Chemotherapy 2006 57(5):1008-1009; doi:10.1093/jac/dkl090
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/5/1008    most recent
dkl090v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McNicholas, S.
Right arrow Articles by Cormican, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McNicholas, S.
Right arrow Articles by Cormican, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Correspondence

Linezolid audit: similarities and contrasts with published experience

S. McNicholas1,*, A. Barber2, G. Corbett-Feeney1 and M. Cormican1

1 Department of Medical Microbiology, University College Hospital, Galway, Ireland; 2 Department of Pharmacology, University College Hospital, Galway, Ireland

* Corresponding author. Tel: +353-91-544573; Fax: +353-91-524216; E-mail: Sinead.McNicholas@mailn.hse.ie

Keywords: MRSA , VRE , antibiotic usage

The first 10% of the full text of this article appears below.

Sir,

Ziglam et al.1 have recently reported an audit of linezolid use in a hospital in Scotland for the period March 2001–September 2003. We conducted a similar audit of linezolid use in a 504 bed teaching hospital, to assess the profile of patients prescribed linezolid, clinical and microbiological indications for treatment, adherence to the licensed indications and product specifications, and documented adverse events. . . . [Full Text of this Article]

Transparency declarations


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?